WILMINGTON

Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations

Retrieved on: 
Thursday, May 9, 2024
8-K, Security (finance), OTCQX, File

MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and to suspend its reporting obligations under Section 15(d) of the Exchange Act.

Key Points: 
  • MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and to suspend its reporting obligations under Section 15(d) of the Exchange Act.
  • The Company’s obligation to file periodic reports with the SEC, including reports on Forms 10-K, 10-Q and 8-K, will be suspended immediately upon filing of the Form 15.
  • Once the Form 15 is effective, which is expected to occur within 90 days of filing, the Company will no longer be a public reporting company and its obligations to file other reports with the SEC will also be suspended.

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

Retrieved on: 
Thursday, May 9, 2024
Citizenship, Conference

WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Life Sciences Conference, taking place in New York City on May 13 and 14.

Key Points: 
  • WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Life Sciences Conference, taking place in New York City on May 13 and 14.
  • ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat.
  • A live webcast of the fireside chat can be accessed here and on the Company’s website under Events and Presentations .
  • The recording will be archived and available on the Company’s website for 90 days.

Acorn’s Q1’24 EPS Improves to $0.03 vs. ($0.03) Loss Per Share on Continued Growth in Remote Monitoring and Control Hardware and Services Revenue

Retrieved on: 
Thursday, May 9, 2024
OV2, EPA, ERCOT, Research, Exercise, Electricity generation, Optimism, AQI, Marketing, Cathodic protection, Atmosphere, Growth, C&I

Acorn achieved solid growth in new monitoring hardware sales and continued to build on our base of annually recurring, high-margin monitoring service revenue.

Key Points: 
  • Acorn achieved solid growth in new monitoring hardware sales and continued to build on our base of annually recurring, high-margin monitoring service revenue.
  • “We continue to advance the rollout of OmniMetrix Demand Response (DR) programs within the standby generator market.
  • The decrease in gross margin was primarily attributable to a higher proportion of hardware in the revenue mix versus monitoring revenue, which carries a higher gross margin.
  • Acorn’s Q1’24 profitability improvement was driven by revenue and gross profit growth that significantly exceeded increases in operating expenses.

Ashland Board appoints Ashish K. Kulkarni as new director

Retrieved on: 
Wednesday, May 8, 2024
Safety, ROI, Celanese, Ashland Global, General Electric, Policy, GAF, Biophysical environment, Retirement, Avantor, United Technologies, Management

WILMINGTON, Del., May 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) is announcing the appointment of Ashish K. Kulkarni to its Board of Directors.

Key Points: 
  • WILMINGTON, Del., May 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) is announcing the appointment of Ashish K. Kulkarni to its Board of Directors.
  • Kulkarni is the CEO of Kebotix, a startup company focused on commercializing artificial intelligence methods into new material commercialization.
  • With the addition of Kulkarni and in anticipation of potential director retirements under the Board’s retirement and resignation policy, Ashland increases the size of the Board to 11 members.
  • “I am pleased to welcome Ashish as a new director to the Ashland Board,” said Guillermo Novo, chair and chief executive officer, Ashland.

RAIR Technologies launches RAIRprotocol - Open source infrastructure for enterprise dApp development

Retrieved on: 
Wednesday, May 8, 2024
Cloud, Alchemy, Risk, Google Cloud, Dapp, Conference, Software as a service, API, Web 2.0, RAIR, NFT, HashiCorp, DRM, Cryptocurrency

LOS ANGELES [Tokenize LA Conference], May 08, 2024 (GLOBE NEWSWIRE) -- RAIR Technologies today announced the launch of RAIRprotocol , a fully open-source dApp protocol layer.

Key Points: 
  • LOS ANGELES [Tokenize LA Conference], May 08, 2024 (GLOBE NEWSWIRE) -- RAIR Technologies today announced the launch of RAIRprotocol , a fully open-source dApp protocol layer.
  • Developers have the flexibility to utilize RAIR Technologies and RAIRprotocol together or independently, tailoring their approach to suit their specific project requirements.
  • By starting with a working opensource dApp, we can 10x the speed new developers onboard to Web3.” said Garrett Minks, CTO of RAIR Technologies.
  • To learn about the RAIRprotocol and RAIR Technologies’ full suite of now open-source Web3 software, please visit https://rairprotocol.org/ .

Garrett Motion Inc. Announces Upsizing and Pricing of Private Offering of $800 Million of Senior Notes Due 2032

Retrieved on: 
Tuesday, May 7, 2024
Sale, GTX, Offering, Regulation, Rule, Person, Security (finance)

The aggregate principal amount of the Offering of the notes was increased from the previously announced Offering size of $500 million aggregate principal amount of notes.

Key Points: 
  • The aggregate principal amount of the Offering of the notes was increased from the previously announced Offering size of $500 million aggregate principal amount of notes.
  • The notes will be sold to investors at 100.00% plus accrued interest, if any, from May 21, 2024.
  • The closing of the Offering of the notes is expected to occur on or about May 21, 2024, subject to customary closing conditions.
  • The notes will be fully and unconditionally guaranteed by each of the Company’s wholly owned restricted subsidiaries that guarantees the Company’s senior secured credit facilities.

Ashland board authorizes quarterly dividend

Retrieved on: 
Tuesday, May 7, 2024
Ashland Global

WILMINGTON, Del., May 07, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock which represents a five percent increase from the previous quarter.

Key Points: 
  • WILMINGTON, Del., May 07, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock which represents a five percent increase from the previous quarter.
  • The dividend is payable on June 15, 2024, to stockholders of record at the close of business on June 1, 2024.
  • As of April 30, 2024, there were 50,128,349 shares of Ashland common stock outstanding.

Ashland signs definitive agreement to sell nutraceuticals business to Turnspire Capital Partners

Retrieved on: 
Tuesday, May 7, 2024
Sale, LLP, Ashland Global, News, Security (finance), Citigroup, Risk, Form 10-K, Annual report, Calendar, Cravath, Swaine & Moore, Fine chemical

WILMINGTON, Del., May 07, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC (“Turnspire”).

Key Points: 
  • WILMINGTON, Del., May 07, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC (“Turnspire”).
  • The transaction is expected to close in the calendar third quarter 2024, subject to the satisfaction of customary closing conditions.
  • “The nutraceuticals business has a strong portfolio of proprietary ingredients, formulation and manufacturing capabilities, and a dedicated team that has demonstrated a passion to grow over the years,” said Guillermo Novo, chair and chief executive officer, Ashland.
  • “I want to thank the employees for their dedication and commitment to Ashland and to our customers.”
    Citi is acting as financial advisor to Ashland.

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 7, 2024
Corporation, Patient, Research and development, Mutation, CDK9, SMARCA4, Safety, Pharmacokinetics, Cancer, Research, Bain & Company, AML, SMARCA2, Growth, Docetaxel, Administration, IND, Senior, ViroPharma, Lead, Toxicity, Acute myeloid leukemia, AACR, Prelude, NSCLC, Lymphoid leukemia, Therapy, G&A, Vertex Pharmaceuticals, Head, Pharmaceutical industry

WILMINGTON, Del., May 07, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the first quarter ended March 31, 2024 and provided an update on recent clinical development pipeline and other corporate developments.  

Key Points: 
  • 2024 AACR Annual Meeting: Prelude participated in the 2024 American Association for Cancer Research Annual Meeting, presenting three preclinical poster presentations.
  • Corporate Updates: In April 2024, Prelude appointed Sean Brusky to the newly created position of Chief Business Officer.
  • Additionally, in April 2024, Prelude appointed Robert Doody to the newly created position of Senior Vice President, Investor Relations.
  • We expect our R&D expenses to vary from quarter to quarter, primarily due to the timing of our clinical development activities.

Symbotic Reports Second Quarter Fiscal Year 2024 Results

Retrieved on: 
Monday, May 6, 2024
Hand, Software

WILMINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Symbotic Inc. (Nasdaq: SYM ), a leader in A.I.-enabled robotics technology for the supply chain, announced financial results for its second fiscal quarter of 2024 ended March 30, 2024.

Key Points: 
  • WILMINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Symbotic Inc. (Nasdaq: SYM ), a leader in A.I.-enabled robotics technology for the supply chain, announced financial results for its second fiscal quarter of 2024 ended March 30, 2024.
  • Symbotic posted revenue of $424 million, a net loss of $41 million and adjusted EBITDA¹ of $22 million for the second quarter of fiscal 2024.
  • In the same quarter of fiscal 2023, Symbotic had revenue of $267 million, a net loss of $55 million and an adjusted EBITDA loss¹ of $11 million.
  • Symbotic will host a webcast today at 5:00 pm ET to discuss its second quarter fiscal 2024 results.